Gene expression microarray data have huge potential for cancer research and treatment. Gene expression profiles have been used to classify tumours ([Bittner *et al*, 2000](#bib6){ref-type="other"}; [Ramaswamy *et al*, 2001](#bib40){ref-type="other"}; [Selaru *et al*, 2002](#bib44){ref-type="other"}; [Shipp *et al*, 2002](#bib45){ref-type="other"}), study the biology of tumour progression and metastasis ([Birkenkamp-Demtroder *et al*, 2002](#bib5){ref-type="other"}; [Ramaswamy *et al*, 2003](#bib39){ref-type="other"}), predict clinical outcomes ([van de Vijver *et al*, 2002](#bib50){ref-type="other"}; [Huang *et al*, 2003](#bib25){ref-type="other"}; [Iizuka *et al*, 2003](#bib26){ref-type="other"}), classify drug resistance ([Hofmann *et al*, 2002](#bib24){ref-type="other"}; [Chang *et al*, 2003](#bib10){ref-type="other"}) and identify novel drug targets ([Marton *et al*, 1998](#bib34){ref-type="other"}). As the technology matures, it is pushing towards mainstream clinical application ([Gershon, 2004](#bib21){ref-type="other"}; [Jarvis and Centola, 2005](#bib27){ref-type="other"}; [Cardoso *et al*, 2008](#bib9){ref-type="other"}). Surmountable challenges remain, such as standardisation and validation of the competing platforms and analysis techniques. However, the heterogeneity of clinical tumour samples remains a fundamental problem which must be addressed ([Winegarden, 2003](#bib54){ref-type="other"}). All cell subpopulations in a sample contribute to the gene expression profile. Relatively homogenous cell populations yield optimal expression data, and increasing ratios of stromal cells may obscure the gene expression of parenchymal cancer cells ([Emmert-Buck *et al*, 1996](#bib17){ref-type="other"}; [Ross *et al*, 2000](#bib41){ref-type="other"}; [Butte, 2002](#bib8){ref-type="other"}; [Sugiyama *et al*, 2002](#bib47){ref-type="other"}). Stromal gene expression may cause misinterpretation of data, with important subtle cancer gene changes being masked by contaminating RNA, and increasing the potential for attributing incorrect functional gene associations ([Smith *et al*, 2003](#bib46){ref-type="other"}). However, interactions between stromal cells and tumour parenchyma are increasingly recognised as an important factor in tumour biology and clinical outcome, and the delineation and retention of stromal gene expression has considerable value ([Fukino *et al*, 2007](#bib19){ref-type="other"}; [Patocs *et al*, 2007](#bib38){ref-type="other"}).

Laser capture microdissection (LCM) allows the selection of specific cells from tissue and could potentially circumvent many of these problems ([Emmert-Buck *et al*, 1996](#bib17){ref-type="other"}). [Sugiyama *et al* (2002)](#bib47){ref-type="other"} examined the expression profile of LCM dissected tissue and whole tissue. They demonstrated significant differences in expression profiles, finding that the overall difference in the gene expression profile was related to levels of stromal contamination. However, LCM is a costly, laborious and highly skilled procedure which yields small quantities of RNA, which renders clinical application impractical ([Liu, 2007](#bib32){ref-type="other"}). It has also been demonstrated by [Michel *et al* (2003)](#bib35){ref-type="other"} that the LCM process introduces a systematic bias into gene expression profiles. Another problem encountered in the estimation of stromal content histologically, and therefore by both LCM and macrodissection, is the 'reference trap\'. A two-dimensional microscopic view of a complex three-dimensional structure, such as a tumour, leads to irreversible qualitative and quantitative loss of information ([Nyengaard, 1999](#bib37){ref-type="other"}). This means that fractions of cells can be grossly under- or overestimated if unbiased sampling methods (i.e. stereological methods) are not used.

Fluorescence cytometry (FC) and fluorescence-activated cell sorting (FACS) allow simultaneous quantitation and multiparametric assessment of the phenotype of cells by staining with fluorochrome-conjugated antibodies ([Afanasyeva *et al*, 2004](#bib2){ref-type="other"}). These are generally used to examine or sort peripheral blood samples ([Waguri *et al*, 2003](#bib52){ref-type="other"}), to identify tumour cells in malignant effusions, to isolate clones and infrequently for the separation of specific cell populations from solid tissue ([Afanasyeva *et al*, 2004](#bib2){ref-type="other"}; [Suzuki *et al*, 2004](#bib48){ref-type="other"}). Advances in laser technology, speed of sorting and range of fluorochromes, make FACS a potentially useful method for identifying and purifying cell populations from solid tumours for analysis. Fluorescence-activated cell sorting overcomes many of the problems associated with LCM and macrodissection, by allowing systematic sampling of a large number of parenchymal tumour cells, allowing confirmation of the purity of targets and potentially, a better average of gene expression in cancer cells. We aimed to evaluate the feasibility of using FACS for producing homogenous cell populations for gene expression microarray analysis of colorectal tumour samples. Specifically, we wished to compare the differences in gene expression profiles elicited from whole tissue and sorted cells.

Materials and methods
=====================

Colorectal carcinoma tissue
---------------------------

Colorectal carcinoma (CRC) tissue samples were obtained, with informed consent, from patients undergoing curative bowel resection ([Table 1](#tbl1){ref-type="table"}). All patients were Irish Caucasians. None of the patients received preoperative chemotherapy or radiotherapy. Three primary cancers were used to compare the gene expression of sorted cells and whole tumour samples, after optimisation of our FACS methodology. Collection of tissue was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.

Generation of a single cell suspension from colorectal cancer tissue
--------------------------------------------------------------------

Tumour samples were washed in Dulbecco\'s modified Eagle\'s medium (DMEM; BioWhittaker, Wokingham, UK) and macroscopic necrotic tissue was excised with a scalpel and washed in DMEM. A portion of the biopsy was immediately snap frozen in liquid nitrogen and stored at −80°C until RNA extraction and approximately 1 g of tumour tissue was mechanically disaggregated, and subsequently enzymatically digested with bovine collagenase II, IV (Sigma-Aldrich, Dublin, Ireland) and DNAse I (Roche, Clarecastle, Ireland) at concentrations of 2 and 1 mg ml^−1^, at room temperature (22°C) for 45--60 min. This mix was then filtered through 70 mm pore mesh (Becton Dickinson, Oxford, UK). All suspensions were generated under standardised environmental conditions, being kept at 4°C, except for the enzyme digestion stage.

Flow cytometry
--------------

Dissociated cells in suspension were incubated on ice with mouse anti-human epithelial antigen (HEA) monoclonal antibody (mAb) conjugated with FITC (clone BER-EP4; Dako, Glostrup, Denmark), anti-CD14 mAb conjugated with phycoerythrin (PE) and anti-CD45 conjugated with PerCP mAb (both from BD Pharmingen, Erembodegem-Aalst, Belgium) or relevant isotype controls, for 45 min. The labelled cells were analysed and separated using FACS Vantage with CellQuest Pro software (Becton Dickinson). Establishment of the gates was based on the staining profiles of the negative controls, positive controls (SW-620 cells, labelled with HEA) and to eliminate low forward scatter signal events, eliminating debris, red cells and apoptotic cells.

The mAb BER-EP4 binds to a partially formol-resistant epitope on the protein moiety of two 34- and 39 kDa glycopolypeptides on human epithelial cells. It does not bind to any non-epithelial cells ([Latza *et al*, 1990](#bib30){ref-type="other"}). Specifically, it does not bind to mesenchymal or lymphoid tissue. However, in large cell populations antibodies can bind in a non-specific manner. To control for this, we blocked antibodies with 1% fetal calf serum and used isotype control antibodies as negative controls. There is also a possibility of immune cells expressing the HEA antigen after ingestion of apoptotic cells. As immune cell infiltrate is a large component of stromal tissue, we decided to use antibodies to allow us to quantify and negatively select immune cells to avoid contamination in our sorted epithelial fraction. Phagocyte numbers have been found to increase from 1.5- to 2.5-fold in Duke\'s B and C tumours, respectively, and T cells by 1.4-fold in colorectal tumours ([Allen and Hogg, 1985](#bib3){ref-type="other"}, [1987](#bib4){ref-type="other"}). We decided that a combination of antibodies binding to CD14, which is the LPS receptor and is expressed strongly on the surface of monocytes, weakly on the surface of granulocytes and by most tissue macrophages, and CD45, a tyrosine phosphatase a critical requirement for T- and B-cell antigen receptor-mediated activation, which is expressed, typically at high levels, on all haematopoietic cells (expression is at a higher density on lymphocytes, approximately 10% of surface area is CD45), would be the ideal combination. It has previously been demonstrated that using positive selection of HEA-expressing cells and negative selection of CD45- or CD14-expressing cells yields using immunomagnetic cell sorting lead to high yields of epithelial cells from cell solutions ([Zigeuner *et al*, 2000](#bib55){ref-type="other"}; [Guo *et al*, 2004](#bib23){ref-type="other"}).

Cell sorting and confirmation of cell phenotype
-----------------------------------------------

A one-step, three-colour, sorting approach was used. Our goal was to positively select colorectal parenchyma and negatively select for stromal cells. A diagram illustrating the method is shown in [Figure 1](#fig1){ref-type="fig"}. Sorting gates were set for positive selection of HEA^+^ CD14^−^ CD45^−^ and negative selection of HEA^−^ CD14^+^ CD45^+^ cells. Unstained cells, cells stained with isotype controls, were used for all samples, and SW-620 cells were used as a positive control for CRC cells. At least 7 million HEA^+^ cells were sorted, as below this level we found RNA quantity was variable. Cells were sorted into BD polypropylene flow tubes coated with 4% bovine serum albumin (Sigma-Aldrich). Purity of the sample was checked after sorting by reanalysing HEA^+^ CD14^−^ CD45^−^ fraction, on the same machine, after a full cleaning protocol. Purity greater than 90% was deemed acceptable.

After sorting, cells were confirmed to be colorectal tumour cells by microscopic examination, by cytospinning on to Superfrost Plus microscope slides (BDH Laboratory Supplies, Poole, UK) followed by ethanol fixation and staining with Rapi-Diff (Cytocolor, Hinckley, OH, USA) or immunocytochemistry. Immunocytochemistry was performed using Dako MNF-116 anti-pan-cytokeratin antibody, using the standard EnVision kit protocol (Dako).

We have also applied this method to successfully purify tumour parenchyma in CRC liver metastases, primary breast tumours, and with modification, to sort breast cancer bone marrow micrometastases.

RNA isolation
-------------

RNA was extracted from three corresponding whole tumour samples and FACS-purified tumour parenchyma using a modification of the Tri Reagent (Molecular Research Center, Cincinnati, OH, USA) protocol ([Curtin and Cotter, 2004](#bib12){ref-type="other"}). RNA with an absorbance ratio A260/240 \>1.8 and no evidence of RNA degradation by gel electrophoresis was accepted. We then checked the RNA quality using the Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA) runs. We used RNA with a RIN (RNA integrity number) value ⩾8 ([Schroeder *et al*, 2006](#bib42){ref-type="other"}).

cRNA preparation
----------------

The labelling of the total RNA was performed according to the 'Small Sample Labeling Protocol vII\' (Affymetrix, Santa Clara, CA, USA). Total RNA (100 ng) was used as starting material for the first round of cDNA preparation. The first and second strand cDNA synthesis was performed using the Superscript II system (Invitrogen, Dublin, Ireland) according to the manufacturer\'s instructions except using an oligo-dT primer containing a T7 RNA polymerase promoter site. The first round of *in vitro* transcription (IVT) was performed using the MEGAscript T7 kit (Ambion, Warrington, UK). The second round of cDNA preparation was done as first round except now random hexamers replaced the oligo-dT primer.

Labelled cRNA was prepared using the BioArray High Yield RNA Transcript Labeling Kit (Enzo, Farmingdale, NY, USA). Biotin labelled CTP and UTP (Enzo) were used in the reaction together with unlabelled NTPs. During the labelling, the IVT product and also the fragmented IVT product were checked by gel electrophoresis. Following the IVT reaction, the unincorporated nucleotides were removed using RNeasy columns (Qiagen, Crawley, UK).

Oligonucleotide array hybridisation and scanning
------------------------------------------------

Fragmented cRNA was loaded onto the GeneChip HU133 Plus 2.0 probe array cartridge (Affymetrix). The washing and staining procedure was performed in the Affymetrix Fluidics Station 450 (Affymetrix). The biotinylated cRNA was stained with a streptavidin--PE conjugate, and the probe arrays were scanned at 560 nm using a confocal laser-scanning microscope (Affymetrix Scanner 3000; Affymetrix). After hybridisation and scanning, we checked several quality parameters: scaling factor ⩽3-fold difference within a study; 3′/5′ ratio for probe sets for GAPDH ⩽3; present (P) calls in the same range for all samples in the study and RawQ below 100. All of our arrays passed all stages of the quality control. The readings from the quantitative scanning were analysed by the Affymetrix Gene Expression Analysis Software (Affymetrix).

Statistical analysis of gene expression data
--------------------------------------------

Affymetrix GeneChip array data were normalised, pre-processed and analysed using R and Bioconductor statistical software ([Gentleman *et al*, 2004](#bib20){ref-type="other"}). Raw CEL file data from human whole genome Affymetrix U133Plus2 gene GeneChips of purified 'of whole primary\' colon cancer samples (*n*=3) and tumour parenchyma samples purified by FACS (*n*=3) were imported into R. Initial exploratory data analysis performed using the overview function in the package made4 ([Culhane *et al*, 2005](#bib11){ref-type="other"}) suggested that the assumption of a constant sum across all microarray samples may not be valid for these data. Moreover, there were significantly more MAS 5.0 P calls in the whole samples than in the FACS-purified samples (paired *t*-test, *P*\<0.05). Therefore, data were normalised using the Li and Wong\'s invariant set method using the 'expresso\' function in the Affy package in Bioconductor ([Li and Hung Wong, 2001](#bib31){ref-type="other"}; [Gentleman *et al*, 2004](#bib20){ref-type="other"}). Normalised data were log2 transformed and assessed initially using use two exploratory data analysis approaches: hierarchical cluster analysis (1-Pearson correlation coefficient distance with average linkage joining) and dimension reduction using correspondence analysis (COA; [Eisen *et al*, 1998](#bib16){ref-type="other"}; [Fellenberg *et al*, 2001](#bib18){ref-type="other"}). Figures were created using the made4 package in Bioconductor ([Culhane *et al*, 2005](#bib11){ref-type="other"}).

Detection of genes differentially expressed in purified tumour
--------------------------------------------------------------

Given the low number of replicates in this study, it is challenging to estimate of gene mean and variance; therefore, rank-based non-parametric methods may be more efficient in these data. It is reported that rank product performs comparably or outperforms *t*-statistic-based methods when replicates numbers are very low (less than five) ([Breitling *et al*, 2004](#bib7){ref-type="other"}; [Jeffery *et al*, 2006](#bib28){ref-type="other"}). Rank products analysis is a non-parametric statistic that detects genes that are consistently highly ranked in lists, that is genes that are consistently upregulated genes in a number of replicate experiments. Rank products analysis does not require a measure of gene-specific variance and is therefore particularly powerful when only a small number of replicates are available. Rank products analysis was performed using the Bioconductor package RankProd. False discovery rates were estimated using 100 permutations.

To aid interpretation of these genes lists, we used DAVID to assess which Gene Ontology biological and functional categories were overrepresented in this list of genes ([Dennis *et al*, 2003](#bib15){ref-type="other"}). We used the highest stringency level, for other analyses we used an EASE of 0.01, and false discovery rate of 1000. Heatmap images of gene expression profiles were generated using the made4 package in Bioconductor. The Human Genome Organisation (HUGO) gene symbols for Affymetrix probe sets were retrieved using the annaffy Bioconductor package and the annotation library hu133plus2 (build Tuesday, 4 October 2005, 20:53:27).

Results
=======

Patient demographics and FACS
-----------------------------

Three matched patient biopsies were taken immediately after resection. No patients received pre-operative chemoradiotherapy. Metastases (m1) were observed intra-operatively in one patient. The other patients were free from metastases (mx). Histological examination of the E1 and E12 samples demonstrated moderately differentiated adenocarcinomas with strand-like infiltrative pattern of malignant glands through muscularis propria, interspersed by stroma. The E6 sample demonstrated a well-differentiated adenocarcinoma with closely packed glands invading into muscularis propria, with stroma between the glands. After generation of single cell suspensions from our experimental tumour biopsies, stromal content was estimated to range from 37 to 60%, and sorted to greater than 90% purity as described earlier ([Figure 2](#fig2){ref-type="fig"}). The parenchymal component of the tumours was estimated to range from 50 to 80% on histological assessment. The E6 sample demonstrated the biggest discrepancy in estimation of parenchymal content (FC estimate 37 *vs* 80% histological assessment), which may be explained by the fact that the sample contained a large muscularis propria component, which could account for the high proportion of non-staining FC events. Sorted cells were subsequently confirmed as tumour parenchyma by light microscopy assessment ([Figure 3](#fig3){ref-type="fig"}). We found the sorted cell population was homogenous and had the morphological appearances consistent with CRC cells after staining with Rapi-Diff and comparison to SW-620 colorectal cell line. The cells also stained positive for the cytokeratin MNF-116, confirming they were epithelial in nature. Using FC we found that the population of HEA^+^ cells fluoresced in the same region as cells stained with MNF-116.

Differential gene expression
----------------------------

There were significantly more MAS 5.0 P calls in the whole samples than in the FACS-purified samples (paired *t-*test, *P*\<0.05; [Figure 4](#fig4){ref-type="fig"}). Ordination was used to explore the data, and correspondence analysis was applied to the data using the made4 package in Bioconductor ([Culhane *et al*, 2005](#bib11){ref-type="other"}). Correspondence analysis is a useful dimension reduction method for observing the *χ*^2^ or associations between genes and samples. The dendrogram showed that the whole and the purified samples could be portioned into two distinct clusters ([Figure 5A](#fig5){ref-type="fig"}). These clusters were also observed on the most variant or first axis of a COA of these data (Fellenberg *et al*, 2001) ([Figure 5B](#fig5){ref-type="fig"}). Interestingly, the second most variant axis (F2, vertical) separated the metastatic (E1) and metastatic-free samples. Although we have few replicates in this study, it appeared that metastatic and metastatic-free tumour samples were more defined in the purified samples when compared to the whole samples. The discrimination between metastatic and metastatic-free samples accounted for more variance than difference between tumour stage.

Expression of 289 genes were detected in whole-biopsy samples but not in purified samples (*P*\<0.05). Of these, 50 differentially expressed genes were highly significant (*P*\<0.01; [Table 2](#tbl2){ref-type="table"}). Expression of 103 genes were detected in purified samples, but significantly downregulated in whole samples (*P*\<0.05), of which 33 of these were significant at *P*\<0.01 ([Table 3](#tbl3){ref-type="table"}) which are displayed in the Heatmaps in. Heatmaps of the highly significant differentially expressed genes were generated, and displayed in [Figure 6](#fig6){ref-type="fig"}.

Functional annotation
---------------------

We used DAVID to classify gene function in the whole tumour sample ([Table 4](#tbl4){ref-type="table"}). Most functional classes are consistent with stromal as opposed to tumour cell function (e.g., proteinaceous extracellular matrix *P*=2.37 × 10^−08^, extracellular matrix *P*=2.49 × 10^−08^, collagen triple helix repeat *P*=7.12 × 10^−07^), although genes known to be expressed in tumour epithelium were identified (e.g., *GREM1*). Looking at individual genes, upregulation of connective tissue genes was prevalent (e.g., *COL6A3, COL1A2, COL12A1, COL5A2, COL3A1, CTHRC1, SULF1*), as were genes involved in extracellular matrix function (e.g., *LAMA4, PI3, POSTN, TIMP2*) and cell adhesion (e.g., *TNS1*). Genes involved in endothelial function (e.g., *TIMP2*) and specifically, colon cancer tumour endothelium, such as the anthrax toxin receptor (*ANTXR1*), were also upregulated ([Liu *et al*, 2008](#bib33){ref-type="other"}).

In contrast, the 31 highly significantly expressed genes in the FACS-purified cells do not display characteristics of stromal gene expression, and may be representative of tumour parenchyma gene expression. Genes involved in cell signalling, such as *SQSTM1*, which regulates activation of the nuclear factor-*κ*B (NF-*κ*B) signalling pathway, receptor internalisation, and protein turnover, and *RRAD*, a member of the Ras/GTPase superfamily, are also overexpressed ([Moyers *et al*, 1997](#bib36){ref-type="other"}; [Seibenhener *et al*, 2007](#bib43){ref-type="other"}). Genes known to be expressed in CRC were also significantly upregulated, such as *HOX2D* and *RHOB*, which mediate apoptosis in neoplastic cells, and are targets for novel antitumour agents, such as farnesyltransferase inhibitors ([Vider *et al*, 1997](#bib51){ref-type="other"}; [Delarue *et al*, 2007](#bib14){ref-type="other"}).

Comparison with Kwong *et al* expression signature
--------------------------------------------------

[Kwong *et al* (2005)](#bib29){ref-type="other"} examined the expression signature derived from 60 tumours (normal mucosa, adenoma, tumour and liver metastases) and identified an expression profile that was able to differentiate between normal and neoplastic samples, but not individual tumour stages. They suggested that stromal genes may obscure the subtle molecular changes in tumours of differing pathological stage. Examination of their gene list, specifically the 34 upregulated genes in their signature, reveals the expression of extracellular matrix proteins such as, collagen, type I, *α*1 (*COL1A1*) and fibronectin. The authors believe this represented gene expression derived from infiltrating lymphocytes and other stroma. The gene list they identified shares similarities to gene expressed in our whole tumour sample (*ANTXR1, COL12A1, COL5A2, CTHRC1, POSTN*).

Discussion
==========

Our study demonstrates that it is feasible to reproducibly separate and purify tumour parenchyma and other cell populations from a single cell suspension generated from a solid tumour using FACS. We also found that the gene expression profile elicited from the whole tumour was significantly different from that of the purified tumour parenchyma, and that source of this differential expression may be tumour stroma. When tumour parenchymal purity is necessary, FACS may be an alternative to LCM, in particular in tumours such as CRC, melanoma and other non-sclerotic tumours amenable to the generation of a single cell suspension.

In our samples, we noted a large variance in estimated quantity of tumour parenchyma and stroma. Using FC we estimated that the parenchymal component of the tumours ranged from 37 to 60% and stroma from 40 to 63%. This was enriched to over 90% (range 90--96%) in each case with one sorting run per sample after calibration of the machine and settings for each sample. Verification of cell type is straightforward with standard staining techniques. We believe this level of stroma would grossly affect the gene expression profile taken from the biopsy and would be in keeping with the findings of [Sugiyama *et al* (2002)](#bib47){ref-type="other"}.

For publication we specifically used rank products as this has been shown to be reliable in small sample sizes in microarray experiments ([Breitling *et al*, 2004](#bib7){ref-type="other"}; [Jeffery *et al*, 2006](#bib28){ref-type="other"}). We found that the expression profile in the whole elicited also made biological sense. We are confident that there are real differences in the gene identified, which are related to the stromal gene expression, and that this has implications for clinical application of gene expression microarrays in CRC.

The MammaPrint assay, which is a clinical application of the van't Veer 70-gene breast cancer expression profile, relies on a single fresh sample of tumour to predict prognosis ([van 't Veer *et al*, 2002](#bib49){ref-type="other"}; [Cardoso *et al*, 2008](#bib9){ref-type="other"}). The samples are examined, and a stromal content of \<50% is deemed acceptable for the test. This would arguably eliminate two of our samples from analysis, which we were able to enrich to \>90% purity. However, [Wang *et al* (2004)](#bib53){ref-type="other"}, who derived an expression profile predicting recurrence of Duke\'s B colorectal carcinoma, included only samples that were enriched to over 85% purity. We believe that in CRC samples, the stroma will contaminate the sample causing problems with patient classification, but that can be overcome with parenchymal purification. The optimal tumour/stroma ratio for gene expression studies is yet to be determined and may vary depending on the tumour type.

To ensure good quality expression data, we used several layers of quality control, starting with RNA gel electrophoresis and then checking RNA integrity with the Agilent Bioanalyzer (Agilent). Subsequently, after hybridisation and scanning, we checked several quality parameters such as scaling factor, 3′/5′ ratios, P calls and RawQ values. Quantitative RT--PCR was not employed as all of our arrays passed all stages of the quality control, and we do not believe that it will be used in clinical practice. This has been borne out by the current application of the MammaPrint assay and is a similar approach to other clinical microarray studies ([Wang *et al*, 2004](#bib53){ref-type="other"}; [Glas *et al*, 2006](#bib22){ref-type="other"}; [Ach *et al*, 2007](#bib1){ref-type="other"}; [Cardoso *et al*, 2008](#bib9){ref-type="other"}).

We found a significant difference in the total number of probes called as present using the Affymetrix MAS5 signal algorithm. This shows that the whole tissue expressed a larger number of genes than sorted cells, demonstrating the wide range of genes expressed by non-tumour cells. We used Li and Wong\'s invariant set method for normalisation of the data sets ([Li and Hung Wong, 2001](#bib31){ref-type="other"}). This uses a set of non-differentially expressed genes to normalise data that are identified by using an iterative procedure. Gene expression common to the sorted cells and whole tissue should be reasonably uniform. Any genes found to be expressed in the whole tissue can be presumed to be contained in stromal tissue. We then sought to examine how similar the gene expression profile of each sample was. Using hierarchical clustering, all three sorted samples clustered together, as did the whole-tissue samples clustered together. Correspondence analysis also showed a clear separation of sorted samples and whole-tissue samples. The E1 and E1W sample also separated from the other samples. This is not surprising as this sample was from a more advanced tumour than the others. The stromal component of the whole-tissue sample was the biggest determinate in differences and could easily separate all samples. This may explain why some studies show very similar GEP throughout tumour stages, and the similarity of some of the genes in our whole tumour sample to that of Kwong *et al* ([Birkenkamp-Demtroder *et al*, 2002](#bib5){ref-type="other"}; [Kwong *et al*, 2005](#bib29){ref-type="other"}). Qualitatively the expression of the whole tumour samples were consistent with tumour stroma, with genes highly specific for colorectal tumour stroma (e.g., *ANTXR1*), and DAVID analysis identifying highly significant functional groups involved in extracellular matrix function. Conversely, FACS-purified parenchyma expressed genes specifically associated with colorectal neoplasia, such as *HOX2D* and *RHOB*. The ability to examine the samples in parallel affords increased precision in analysis of tumour fraction gene expression and offers new opportunities to examine tumour--stroma interactions.

Fluorescence-activated cell sorting parenchymal purification has several advantages over LCM. Disaggregation of a tumour sample generates a large random sample of tumour cells and may elicit a more representative and relevant gene expression profile than LCM, without the need for RNA amplification. Previous studies have assessed the differences between LCM acquired tissue, macrodissection and whole-tissue samples for microarray studies ([Sugiyama *et al*, 2002](#bib47){ref-type="other"}; [Michel *et al*, 2003](#bib35){ref-type="other"}; [de Bruin *et al*, 2005](#bib13){ref-type="other"}). Sugiyama suggests that if the stromal compartment is \>30% LCM should be used, and showed marked differences in GEP in LCM-derived tissue compared with bulk biopsy. Similarly, [Michel *et al* (2003)](#bib35){ref-type="other"} demonstrated that the LCM process introduces a bias into GEP profiles. Although they found that large expression changes were maintained, many genes changed with lower expression levels may be lost. This is problematic for several reasons -- particularly as smaller changes in mRNA expression may have larger effects downstream than larger ones. Also it makes comparisons difficult between studies. Although LCM aims to overcome such problems, the very premise it is built on may introduce bias. A two-dimensional microscope view of a complex three-dimensional structure such as a tumour leads to irreversible qualitative and quantitative loss of information ([Nyengaard, 1999](#bib37){ref-type="other"}). This means that fractions of cells can be grossly under- or overestimated if unbiased sampling methods such as stereological methods are not used (the 'reference trap\'). At worst it can lead to a gene expression profile of a tiny fraction of tumour being misinterpreted as expression of the whole tumour. Macrodissection is subject to similar compromises. Fluorescence-activated cell sorting overcomes many of these problems by allowing systematic sampling of cells, providing a large sample of cells, which allows confirmation of purity of targets and also a better average of gene expression in a tumour.

In conclusion, FACS is effective in producing homogenous cell populations for gene expression microarray experiments in solid tumours and is viable alternative to macrodissection, LCM and whole tumour sampling in microarray experiments. Fluorescence-activated cell sorting overcomes many of the practical and theoretical problems associated with LCM. The gene expression profile of FACS-purified tumour parenchyma is significantly different to that of clinically resected tumour biopsies. Our analysis suggests that stromal gene expression is responsible for the differential expression and makes a significant contribution to the gene expression profile of whole tumour CRC biopsies. Therefore, one should consider a purification strategy when planning solid tumour gene expression microarray experiments. Although many of the sources of technical noise and variation in gene expression microarray technology have been overcome, there remain challenges, such as the approach to tumour heterogeneity, which need to be overcome before it is accepted into clinical practice.
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![This figure demonstrates our method for separating tumour stroma and parenchymal cells using fluorescence-activated cell sorting. Briefly, debris is gated out, target populations identified and positively (parenchyma) or negatively selected (stroma). Dot plots represent 10 000 events, and show side scatter and forward scatter plots in Step 1 and fluorescence plots in Steps 2 and 3. Cells have been simultaneously stained with mouse anti-human anti-HEA, anti-CD14 and anti-CD45 monoclonal antibodies conjugated with FITC, PE and PerCP, respectively, which are resolved on FL-1, FL-2 and FL-3. Step 1 demonstrates our method of gating out debris and identification of the HEA positive population with scatter plots. Step 2 demonstrates the identification of CD45 (A) and CD14 (B) positive populations, followed by gating of HEA+CD14 population (C) and gating of HEA+ CD14-CD45-population (D), which consists of 43% of cells. Step 3 is the identification and selection of the R3 region (HEA+ CD14- CD45- population) for cell sorting, and the estimation of presorting parenchymal content, which is estimated at only 43% of cells in this sample. After cell sorting the flow cytometer is cleaned, and the post-sorting populations evaluated. Step 4 shows a histogram demonstrating the post-sorting populations of cells. The histogram plots the fluorescence of HEA^+^ cells on FL-1 (region M2) against counts on the *y*-axis. There is clear separation of the tumour parenchyma (M2 region) and the stromal (M1 region) cells. We estimate the populations have a purity of over 90%.](6604931f1b){#fig1}

![Fluorescence-activated cell sorting of CRC cells from experimental samples. We generated single cell suspensions from three patient samples and sorted them to greater than 90% purity in each case. Dot plots show the pre- and post-sorting HEA^+^ populations. The table shows the estimates of tumour cell purity in the samples and the initial histological estimates of tumour parenchyma content. We sorted an average of 9 million cells per sample.](6604931f2){#fig2}

![Cytological confirmation of cell-sorted tumour parenchyma. To confirm that our HEA^+^ CD14^−^ CD45^−^ cell population was tumour parenchyma, we examined three post-sorting populations after cytospinning and Rapi-Diff II (Diagnostic Developments) staining and compared them to SW-480 cells, a cell line derived from a primary colorectal tumour ( × 40 magnification shown). Then we confirmed the cells were epithelial by staining with MNF-116 pan-cytokeratin (Dako).](6604931f3){#fig3}

![Differential gene expression between whole tumour and cell-sorted colorectal cancer biopsies. This graph displays the genes called as presented by MAS 5.0 in each sample (P, present; A, absent; M, marginal). There was a significant difference in genes called as present in the whole-tissue samples (*P*=0.0407, Student\'s paired *t*-test). These genes are therefore expressed in non-parenchymal (or stromal) tissue.](6604931f4){#fig4}

![Hierarchical clustering using Eisen\'s formula of a correlation similarity metric and average linkage clustering led to the cell-sorted samples and whole-tissue samples clustering together, showing they are most similar to each other (**A**). This is despite the fact that they are paired samples. Correspondence analysis also demonstrates that the sorted samples and whole-tissue samples cluster together (**B**). The first axis (horizontal) splits the whole and FACS-purified samples. The second axis (vertical) split E1 and E1W from E6, E12, E12W and E6W. Genes that separate the samples are shown with HUGO classification.](6604931f5){#fig5}

![Genes detected by rank products analysis (*P*\<0.01). Heatmaps showing the differentially expressed genes detected in whole but not purified samples (**A**) and purified but not whole samples (**B**) using rank product analysis (*P*\<0.01) using *Z*-score normalised values (row centred). Red tiles represent upregulated genes and blue represent downregulated genes.](6604931f6b){#fig6}

###### 

Microarray sample details

  **CEL file name**   **Patient**   **Sample type**   **TNM classification**   **Stage**   **Location**   **Sex**   **Age (years)**
  ------------------- ------------- ----------------- ------------------------ ----------- -------------- --------- -----------------
  A053-04-E1          E1            FACS              T4N0M1                   IV          Caecum         Female    68
  A053-03-E6          E6            FACS              T2N0Mx                   I           Rectosigmoid   Male      55
  A053-05-E12         E12           FACS              T3N0Mx                   IIA         Sigmoid        Male      35
  A053-06-E1W         E1            Whole tissue      T4N0M1                   IV          Caecum         Female    68
  A053-07-E6W         E6            Whole tissue      T2N0Mx                   I           Rectosigmoid   Male      55
  A053-08-E12W        E12           Whole tissue      T3N0Mx                   IIA         Sigmoid        Male      35

###### 

Genes called significant in whole tumour (*P*\<0.01, rank products)

  **Probe set ID**   **Gene symbol**   **Gene title**                                                                                      **RP/Rsum**   **pfp**
  ------------------ ----------------- --------------------------------------------------------------------------------------------------- ------------- ---------
  207961_x\_at       *MYH11*           Myosin, heavy chain 11, smooth muscle                                                               53.331        0
  218469_at          *GREM1*           Gremlin 1, cysteine knot superfamily, homolog (*Xenopus laevis*)                                    18.3444       0
  205594_at          *ZNF652*          Zinc-finger protein 652                                                                             123.6405      0.0011
  226663_at          *ANKRD10*         Ankyrin repeat domain 10                                                                            122.7271      0.0013
  201438_at          *COL6A3*          Collagen, type VI, *α*3                                                                             113.3836      0.0014
  212764_at          *ZEB1*            Zinc finger E-box-binding homeobox 1                                                                139.7127      0.0015
  224823_at          *MYLK*            Myosin light chain kinase                                                                           108.5523      0.0017
  228030_at          ---               Transcribed locus, strongly similar to NP_005768.1 RNA-binding motif protein 6 \[*Homo sapiens*\]   138.618       0.0017
  212077_at          *CALD1*           Caldesmon 1                                                                                         134.6639      0.0018
  206199_at          *CEACAM7*         Carcinoembryonic antigen-related cell adhesion molecule 7                                           133.868       0.002
  212354_at          *SULF1*           Sulfatase 1                                                                                         93.7657       0.002
  235028_at          ---               CDNA FLJ42313 fis, clone TRACH2019425                                                               70.702        0.0025
  230269_at          ---               Transcribed locus                                                                                   145.6395      0.0029
  241879_at          ---               Transcribed locus                                                                                   64.2024       0.0033
  227260_at          *ANKRD10*         Ankyrin repeat domain 10                                                                            201.5746      0.0064
  227061_at          ---               CDNA FLJ44429 fis, clone UTERU2015653                                                               209.8229      0.0066
  202202_s\_at       *LAMA4*           Laminin, *α*4                                                                                       200.6896      0.0067
  218468_s\_at       *GREM1*           Gremlin 1, cysteine knot superfamily, homolog (*Xenopus laevis*)                                    194.7291      0.0067
  238750_at          ---               Transcribed locus                                                                                   211.7612      0.0067
  225269_s\_at       *C2orf12*         Chromosome 2 open-reading frame 12                                                                  183.4678      0.0068
  227140_at          ---               CDNA FLJ11041 fis, clone PLACE1004405                                                               197.6319      0.0068
  203691_at          *PI3*             Peptidase inhibitor 3, skin-derived (SKALP)                                                         200.1168      0.0069
  208747_s\_at       *C1S*             Complement component 1, s subcomponent                                                              194.1383      0.007
  221748_s\_at       *TNS1*            Tensin 1                                                                                            185.7447      0.007
  225681_at          *CTHRC1*          Collagen triple helix repeat containing 1                                                           215.9928      0.0071
  1557270_at         ---               CDNA FLJ36375 fis, clone THYMU2008226                                                               171.7643      0.0072
  202404_s\_at       *COL1A2*          Collagen, type I, *α*2                                                                              191.9636      0.0073
  225786_at          *LOC284702*       Hypothetical protein LOC284702                                                                      162.5829      0.0073
  225664_at          *COL12A1*         Collagen, type XII, *α*1                                                                            166.478       0.0075
  243134_at          ---               Transcribed locus                                                                                   219.3881      0.0075
  210809_s\_at       *POSTN*           Periostin, osteoblast-specific factor                                                               188.6781      0.0076
  225275_at          *EDIL3*           EGF-like repeats and discoidin I-like domains 3                                                     171.1717      0.0076
  221729_at          *COL5A2*          Collagen, type V, *α*2                                                                              231.1445      0.0086
  202948_at          *IL1R1*           Interleukin 1 receptor, type I                                                                      252.7068      0.0087
  225107_at          *HNRNPA2B1*       Heterogeneous nuclear ribonucleoprotein A2/B1                                                       243.1025      0.0087
  226731_at          *PELO*            Pelota homolog (*Drosophila*)                                                                       246.3912      0.0087
  209656_s\_at       *TMEM47*          Transmembrane protein 47                                                                            230.2568      0.0088
  218353_at          *RGS5*            Regulator of G-protein signaling 5                                                                  254.393       0.0088
  224565_at          *TncRNA*          Trophoblast-derived noncoding RNA                                                                   273.7687      0.0088
  212067_s\_at       *C1R*             Complement component 1, r subcomponent                                                              241.6854      0.0089
  201852_x\_at       *COL3A1*          Collagen, type III, *α*1 (Ehlers-Danlos syndrome type IV, autosomal dominant)                       271.8757      0.009
  208782_at          *FSTL1*           Follistatin-like 1                                                                                  268.8627      0.009
  212353_at          *SULF1*           Sulfatase 1                                                                                         265.4504      0.0091
  221778_at          *JHDM1D*          Jumonji C domain containing histone demethylase 1 homolog D (*S. cerevisiae*)                       229.742       0.0091
  224694_at          *ANTXR1*          Anthrax toxin receptor 1                                                                            268.3533      0.0091
  225809_at          *DKFZP564O0823*   DKFZP564O0823 protein                                                                               261.4881      0.0091
  215076_s\_at       *COL3A1*          Collagen, type III, *α*1 (Ehlers-Danlos syndrome type IV, autosomal dominant)                       240.3341      0.0092
  1555878_at         *RPS24*           Ribosomal protein S24                                                                               260.4235      0.0093
  201540_at          *FHL1*            Four-and-a-half LIM domains 1                                                                       258.0377      0.0093
  231579_s\_at       *TIMP2*           TIMP metallopeptidase inhibitor 2                                                                   265.3035      0.0093

###### 

Genes called significant in FACS purified CRC cells (*P*\<0.01, rank products)

  **Probe set ID**   **Gene symbol**   **Gene title**                                         **RP/Rsum**   **pfp**
  ------------------ ----------------- ------------------------------------------------------ ------------- ---------
  200664_s\_at       *DNAJB1*          DnaJ (Hsp40) homolog, subfamily B, member 1            68.0709       0
  204018_x\_at       *HBA1*            Haemoglobin, *α*1                                      66.0374       0
  209116_x\_at       *HBB*             Haemoglobin, *β*                                       10.5524       0
  209458_x\_at       *HBA1*            Haemoglobin, *α*1                                      60.4785       0
  211699_x\_at       *HBA1*            Haemoglobin, *α*1                                      67.0989       0
  211745_x\_at       *HBA1*            Haemoglobin, *α*1                                      52.9371       0
  214414_x\_at       *HBA1*            Haemoglobin, *α*1                                      61.1365       0
  217232_x\_at       *HBB*             Haemoglobin, *β*                                       8.1213        0
  217316_at          *OR7A10*          Olfactory receptor, family 7, subfamily A, member 10   59.4448       0
  217414_x\_at       *HBA1*            Hemoglobin, *α*1                                       28.7839       0
  225762_x\_at       *LOC284801*       Hypothetical protein LOC284801                         9.059         0
  225767_at          ---               ---                                                    42.7413       0
  229667_s\_at       *HOXB8*           Homeobox B8                                            34.4176       0
  204419_x\_at       *HBG1*            Haemoglobin, *γ*A                                      97.798        0.0012
  1565817_at         *IKZF1*           IKAROS family zinc-finger 1 (Ikaros)                   93.4767       0.0013
  211696_x\_at       *HBB*             Haemoglobin, *β*                                       92.8953       0.0013
  209795_at          *CD69*            CD69 molecule                                          92.588        0.0014
  231100_at          *RRAD*            Ras-related associated with diabetes                   135.6185      0.0044
  207574_s\_at       *GADD45B*         Growth arrest and DNA-damage-inducible, *β*            152.1069      0.0052
  208252_s\_at       *CHST3*           Carbohydrate (chondroitin 6) sulfotransferase 3        149.7873      0.0052
  212099_at          *RHOB*            Ras homolog gene family, member B                      151.4472      0.0055
  225377_at          *C9orf86*         Chromosome 9 open-reading frame 86                     145.8861      0.0055
  230935_at          ---               ---                                                    144.722       0.0058
  243001_at          *C18orf22*        Chromosome 18 open-reading frame 22                    167.4874      0.006
  202768_at          *FOSB*            FBJ murine osteosarcoma viral oncogene homolog B       163.3693      0.0062
  210042_s\_at       *CTSZ*            Cathepsin Z                                            174.6238      0.0062
  1569428_at         *WIBG*            Within bgcn homolog (*Drosophila*)                     190.2299      0.0071
  206834_at          *HBB*             Haemoglobin, *β*                                       203.1012      0.0073
  1556262_at         ---               CDNA clone IMAGE:4822139                               208.8925      0.0074
  220369_at          *SMEK1*           SMEK homolog 1, suppressor of mek1 (*Dictyostelium*)   189.2357      0.0074
  244804_at          *SQSTM1*          Sequestosome 1                                         210.7027      0.0075
  235102_x\_at       ---               Transcribed locus                                      199.6653      0.0076
  213515_x\_at       *HBG1*            Haemoglobin, *γ*A                                      223.858       0.0088
  237518_at          ---               Transcribed locus                                      225.91        0.0091

###### 

Functional classification of whole tumour gene expression with DAVID (top 50)

  **Category**      **Term**                                              **Gene count**   **Percentage**   ***P*-value**
  ----------------- ----------------------------------------------------- ---------------- ---------------- ---------------
  GO_CC             Extracellular region part                             15               32.61%           3.87E−10
  GO_CC             Extracellular region                                  17               36.96            6.31E−10
  SP_PIR            Hydroxylation                                         7                15.22            5.82E−09
  GO_CC             Proteinaceous extracellular matrix                    10               21.74            2.37E−08
  SP_PIR            Extracellular matrix                                  9                19.57            2.49E−08
  GO_CC             Extracellular matrix                                  10               21.74            2.71E−08
  SP_PIR            Signal                                                22               47.83            3.88E−08
  GO_CC             Extracellular matrix part                             7                15.22            1.00E−07
  UP_SEQ            Signal peptide                                        22               47.83            1.49E−07
  SP_PIR            Trimer                                                5                10.87            3.61E−07
  INTERPRO          Collagen triple helix repeat                          6                13.04            7.12E−07
  SP_PIR            Triple helix                                          5                10.87            7.53E−07
  SP_PIR            Hydroxylysine                                         5                10.87            8.60E−07
  SP_PIR            Secreted                                              15               32.61            8.62E−07
  GO_BP             Phosphate transport                                   6                13.04            9.47E−07
  SP_PIR            Hydroxyproline                                        5                10.87            1.10E−06
  GO_CC             Collagen                                              5                10.87            1.22E−06
  SP_PIR            Collagen                                              6                13.04            1.24E−06
  SP_PIR            Direct protein sequencing                             18               39.13            2.48E−06
  SP_PIR            Pyroglutamic acid                                     5                10.87            3.81E−06
  SP_PIR            Structural protein                                    6                13.04            6.91E−06
  INTERPRO          Collagen helix repeat                                 5                10.87            7.04E−06
  GO_BP             Organic anion transport                               6                13.04            1.73E−05
  GO_BP             Anion transport                                       6                13.04            3.99E−05
  GO_MF             Extracellular matrix structural constituent           5                10.87            6.54E−05
  KEGG              ECM-receptor interaction                              5                10.87            7.67E−05
  UP_SEQ            Short sequence motif:Cell attachment site             5                10.87            9.21E−05
  PIR_SUPERFAMILY   Collagen *α*1(I) chain                                3                6.52             9.79E−05
  KEGG              Focal adhesion                                        6                13.04            1.39E−04
  SP_PIR            Glycoprotein                                          19               41.30            1.57E−04
  GO_BP             System development                                    13               28.26            1.62E−04
  GO_MF             Structural molecule activity                          9                19.57            1.68E−04
  UP_SEQ            Propeptide:C-terminal propeptide                      3                6.52             1.83E−04
  SP_PIR            Ehlers-Danlos syndrome                                3                6.52             1.89E−04
  GO_BP             Organ development                                     11               23.91            2.43E−04
  GO_BP             Extracellular matrix organization and biogenesis      4                8.70             2.45E−04
  GO_CC             Fibrillar collagen                                    3                6.52             2.71E−04
  INTERPRO          Fibrillar collagen, C-terminal                        3                6.52             2.84E−04
  KEGG              Cell communication                                    5                10.87            4.06E−04
  GO_BP             Multicellular organismal development                  14               30.43            5.90E−04
  GO_BP             Multicellular organismal process                      17               36.96            6.33E−04
  UP_SEQ            Disulphide bond                                       15               32.61            6.92E−04
  SMART             COLFI                                                 3                6.52             7.14E−04
  UP_SEQ            Glycosylation site:N-linked (GlcNAc...)               18               39.13            8.15E−04
  GO_BP             Anatomical structure development                      13               28.26            0.001069024
  UP_SEQ            Domain:VWFC                                           3                6.52             0.001162772
  GO_BP             Extracellular structure organization and biogenesis   4                8.70             0.001291298
  INTERPRO          von Willebrand factor, type C                         3                6.52             0.003487936
  GO_BP             Developmental process                                 15               32.61            0.004413792
  GO_MF             Complement component C1s activity                     2                4.35             0.004676533
  GO_CC             Extracellular space                                   6                13.04            0.005323916
  UP_SEQ            Domain:VWFA 4                                         2                4.35             0.006011568
  SMART             VWC                                                   3                6.52             0.007203275
  SP_PIR            Pyrrolidone carboxylic acid                           3                6.52             0.008914529
  SP_PIR            Skin                                                  2                4.35             0.009320842
